Results 71 to 80 of about 267,145 (352)

Tumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation [PDF]

Clinical Cancer Research, 2019
Abstract Tumor-infiltrating lymphocytes (TIL) are crucial for the success of immunotherapy, and their density can predict prognosis. It has now been shown that computer-based analysis of the spatial organization of TILs adds prognostic value in early-stage non–small cell lung cancer, possibly improving the treatment algorithm to prevent ...
Michael Peled, Roy S. Herbst, Amir Onn
openaire   +3 more sources

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Tumor infiltrating lymphocytes in malignant melanoma - allies or foes?

Biomedical Papers, 2020
This is an overview of current problematics regarding the role of tumor infiltrating lymphocytes (TILs) in malignant melanomas. Various and often conflicting data have been published, correlating tumor type, stage, prognosis, as well as sex and age of ...
Vladimir Zidlik, Michala Bezdekova, Svetlana Brychtova   +2 more
doaj   +1 more source

Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis

Oncoimmunology, 2019
Tumor-infiltrating lymphocytes (TILs) are associated with prognosis in various tumors. However, it remains controversial whether the presence of TILs is related to an improved prognosis in melanoma.
Q. Fu, N. Chen, Chunlei Ge, Ruilei Li, Zhen Li, Baozhen Zeng, Chunyan Li, Ying Wang, Yuanbo Xue, Xin Song, Heng Li, Gaofeng Li   +11 more
semanticscholar   +1 more source

Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma

Frontiers in Immunology, 2021
Primary liver cancer (PLC) is one of the most common malignancies in China, where it ranks second in mortality and fifth in morbidity. Currently, liver transplantation, hepatic tumor resection, radiofrequency ablation, and molecular-targeted agents are ...
Xiaoqin Zheng, Wenji Jin, Shanshan Wang, H. Ding   +3 more
semanticscholar   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors

, 2017
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation
John, Maria, Salgado, Roberto, Gevaert, Thomas, Russell, Prudence A, John, Tom, Thapa, Bibhusal, Christie, Michael, van de Vijver, Koen, Estrada, M V, Gonzalez-Ericsson, Paula I, Sanders, Melinda, Solomon, Benjamin, Solinas, Cinzia, van den Eynden, Gert G G M, Allory, Yves, Preusser, Matthias, Hainfellner, Johannes, Pruneri, Giancarlo, Vingiani, Andre, Demaria, Sandra, Symmans, Fraser, Nuciforo, Paolo, Comerma, Laura, Thompson, E A, Lakhani, Sunil, Kim, Seong-Rim, Schnitt, Stuart, Colpaert, Cecile, Sotiriou, Christos, Scherer, Stefan, Ignatiadis, Michail, Badve, Sunil, Pierce, Robert H, Viale, Giuseppe, Sirtaine, Nicolas, Penault-Llorca, Fred, Sugie, Tomohagu, Fineberg, Susan, Paik, Soonmyung, Srinivasan, Ashok, Richardson, Andre, Wang, Yihong, Chmielik, Ewa, Brock, Jane, Johnson, Douglas B, Balko, Justin, Wienert, Stephan, Bossuyt, Veerle, Michiels, Stefan, Ternès, Nils, Burchardi, Nicole, Luen, Stephen, Savas, Peter, Klauschen, Fred, Watson, Peter H, Nelson, Brad H, Criscitiello, Carmen, O'Toole, Sandra, Larsimont, Denis, de Wind, Roland, Curigliano, Giuseppe, André, Fabrice, Lacroix-Triki, Magali, van de Vijver, Mark, Rojo, Federico, Floris, Giuseppe, Bedri, Shahinaz, Sparano, Joseph, Rimm, David, Nielsen, Torsten, Kos, Zuzana, Hewitt, Stephen, Singh, Baljit, Farshid, Gelareh, Loi, Sibylle, Allison, Kimberly H, Tung, Nadine, Adams, Sylvia, Willard-Gallo, Karen, Horlings, Hugo M, Gandhi, Leena, Moreira, Andre, Hirsch, Fred, Dieci, Maria, Urbanowicz, Maria, Brcic, Iva, Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut, Lo, Amy, Giltnane, Jennifer, Rebelatto, Marlon C, Steele, Keith E, Zha, Jiping, Emancipator, Kenneth, Juco, Jonathan W, Denkert, Carsten, Reis-Filho, Jorge, Loi, Sherene, Fox, Stephen B, Hendry, Shona, Russell, Prudence A., Estrada, M.V., Gonzalez-Ericsson, Paula I., van den Eynden, Gert G.G.M., Thompson, E.A., Pierce, Robert H., Johnson, Douglas B., Watson, Peter H., Nelson, Brad H., O’toole, Sandra, Allison, Kimberly H., Horlings, Hugo M., Rebelatto, Marlon C., Steele, Keith E., Juco, Jonathan W., Fox, Stephen B.   +116 more
openaire   +4 more sources

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

OncoTarget, 2016
Immune checkpoint inhibitors (e.g., anti-PD-1 and anti-PD-L1 antibodies) have demonstrated remarkable efficacy against hypermutated cancers such as melanomas and lung carcinomas.
K. Strickland, B. Howitt, S. Shukla, S. Rodig, Lauren L. Ritterhouse, Joyce F. Liu, J. Garber, Dipanjan Chowdhury, Catherine J. Wu, A. D’Andrea, U. Matulonis, P. Konstantinopoulos   +11 more
semanticscholar   +1 more source